US Stock MarketDetailed Quotes
HOWL Werewolf Therapeutics
- 1.860
- +0.150+8.77%
Trading Aug 8 14:19 ET
80.83MMarket Cap-1690P/E (TTM)
1.990High1.790Low67.24KVolume1.790Open1.710Pre Close125.62KTurnover0.31%Turnover RatioLossP/E (Static)43.46MShares8.19452wk High0.69P/B40.44MFloat Cap1.57452wk Low--Dividend TTM21.74MShs Float23.990Historical High--Div YieldTTM11.70%Amplitude1.390Historical Low1.868Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
Werewolf Therapeutics Stock Forum
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
Werewolf Therapeutics has announced new data from their Phase 1/1b trial of WTX-124, an IL-2 INDUKINETM molecule, in patients with solid tumors. The data, presented at ASCO 2024, highlight WTX-124's clinical activity and tolerability, both as a monotherapy and in combination with pembrolizumab. Three obje...
NEWS
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
Werewolf Therapeutics announced the presentation of updated clinical data from its Phase 1/1b trial of WTX-124, both as monotherapy and in combination with pembrolizumab, at the 2024 ASCO Annual Meeting. The data, current as of January 28, 2024, and updated until May 1, 2024, ...
WTX-124:
•In the first half of 2024, Werewolf expects to present additional interim dose-escalation data from the monotherapy dose-escalation arm, nominate a recommended dose for expansion and initiate monotherapy dose expansion arms.
•Additionally, Werewolf continues to progress combination dose escalation cohorts of the Ph...
✅1️⃣ HOWL Long > 2.73 Short < 2.61
✅2️⃣ NVOS Long > 0.3300 Short < 0.3095
✅3️⃣ CYTO Long > 0.2035 Short < 0.1855
✅4️⃣ PSTV Long > 1.64 Short < 1.49
✅5️⃣ IFRX Long > 1.62 Short < 1.53
✅6️⃣ FUBO Long > 3.20 Short < 2.99
No comment yet